ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

Trial ID or NCT#

NCT01971684

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.

Official Title

ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia

Eligibility Criteria

Ages Eligible for Study: 1 Year to 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Immune Thrombocytopenia or Evans Syndrome - Ages > 12 months to <18 years - Starting a new second line therapy as defined as any therapy except IVIG, steroids, anti-D globulin, or aminocaproic acid - Starting a single agent/monotherapy
Exclusion Criteria:
  1. - Evans Syndrome with a history of or current evidence of autoimmune hemolytic anemia - Unwillingness to be followed for 1 year - Physician providing care is unwilling to participate - Patient is starting multiple second line agents simultaneously
View All Criteria
Show Less

Investigator(s)

Clara Lo

Contact us to find out if this trial is right for you.

Contact

Michael Jeng
6507361177

View on ClinicalTrials.gov